DadFinStart your free week
DadFin › Stocks › Healthcare › SMTI

Sanara MedTech Inc. (SMTI) stock score

Healthcare · Medical Instruments & Supplies · United States

$35.07 ▲ +0.06% today

41.2
Dad Score, out of 100
middling

Sanara MedTech Inc. (SMTI) is a Medical Instruments & Supplies company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 41.2 out of 100 on the Dad Score, a middling reading that places the business ahead of 41% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #515 of 974. Its strongest axes are growth, price action and conviction; its weakest are valuation and quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Below average
Growth
Above average
Price action
Above average
Risk
Below average
Conviction
Strong
Liquidity
Below average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)64.5×
Dividend yield0.00%
Return on capital-56.7%
Operating margin6.3%
Revenue growth (YoY)+19.0%
FCF yield0.6%
Net debt / EBITDA2.60×
Piotroski F-Score4 / 9
52-week change+11.5%
Market cap$320M
Next earningsNov 11, 2026

What subscribers see on SMTI

Start your free weekSubscriber? Open the full research →

Medical Instruments & Supplies peers

StockCompanyDad ScoreBandMarket cap
ISRGIntuitive Surgical, Inc.87.0strong$140.4B
BDXBecton, Dickinson and Company69.8middling$48.2B
MDLNMedline Inc.98.2strong$47.9B
ALCAlcon Inc.64.6middling$30.8B
RMDResMed Inc.94.3strong$30.8B
WSTWest Pharmaceutical Services, Inc.90.1strong$25.7B
SOLVSolventum Corporation71.9good$15.0B
BAXBaxter International Inc.40.5middling$12.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.